Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).
2020
e21683Background: Combination chemo-immunotherapy is a well-established frontline therapeutic option for treatment naive NSCLC. Dual immune checkpoint blockade (ICB) with nivolumab (nivo) and ipili...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI